HLB bioStepLtd Past Earnings Performance
Past criteria checks 0/6
HLB bioStepLtd's earnings have been declining at an average annual rate of -36.8%, while the Life Sciences industry saw earnings growing at 15.4% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-36.8%
Earnings growth rate
-37.0%
EPS growth rate
| Life Sciences Industry Growth | 53.7% |
| Revenue growth rate | 6.5% |
| Return on equity | -5.3% |
| Net Margin | -12.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?
Oct 21
Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?
Jul 17HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely
May 22Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%
Mar 29Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden
Feb 28With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting
Mar 17What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?
Feb 24Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?
Feb 03
Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%
Jan 13Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?
Dec 23Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?
Dec 02Revenue & Expenses Breakdown
How HLB bioStepLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 49,166 | -6,147 | 34,798 | 908 |
| 31 Mar 24 | 50,588 | -2,806 | 33,474 | 724 |
| 31 Dec 23 | 52,814 | -164 | 32,209 | 812 |
| 30 Sep 23 | 62,832 | -1,368 | 36,400 | 342 |
| 30 Jun 23 | 74,209 | -896 | 39,136 | 659 |
| 31 Mar 23 | 82,152 | -1,435 | 41,810 | 929 |
| 31 Dec 22 | 86,277 | -1,008 | 42,834 | 978 |
| 30 Sep 22 | 81,360 | 4,934 | 39,002 | 1,548 |
| 30 Jun 22 | 74,421 | 7,590 | 42,414 | 1,096 |
| 31 Mar 22 | 67,695 | 9,911 | 37,129 | 1,020 |
| 31 Dec 21 | 64,403 | 11,031 | 27,362 | 1,165 |
| 30 Sep 21 | 61,934 | 8,423 | 29,051 | 713 |
| 30 Jun 21 | 58,661 | 8,511 | 25,759 | 713 |
| 31 Mar 21 | 58,528 | 8,463 | 28,050 | 844 |
| 31 Dec 20 | 58,520 | 8,302 | 32,020 | 1,085 |
| 30 Sep 20 | 55,269 | 7,338 | 28,968 | 1,724 |
| 30 Jun 20 | 54,902 | 6,322 | 29,053 | 1,724 |
| 31 Mar 20 | 49,776 | 5,302 | 24,525 | 1,322 |
| 31 Dec 19 | 46,040 | 4,195 | 24,488 | 1,012 |
| 30 Sep 19 | 42,821 | 3,495 | 25,879 | 342 |
| 30 Jun 19 | 41,965 | 4,248 | 23,967 | 342 |
| 31 Mar 19 | 40,390 | 3,816 | 24,423 | 655 |
| 31 Dec 18 | 37,237 | 3,554 | 25,572 | 622 |
| 31 Dec 17 | 29,340 | 4,910 | 13,325 | 846 |
| 31 Dec 16 | 11,158 | 2,435 | 7,256 | 465 |
| 31 Dec 15 | 6,324 | 573 | 3,800 | 136 |
Quality Earnings: A278650 is currently unprofitable.
Growing Profit Margin: A278650 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A278650 is unprofitable, and losses have increased over the past 5 years at a rate of 36.8% per year.
Accelerating Growth: Unable to compare A278650's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A278650 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (12.3%).
Return on Equity
High ROE: A278650 has a negative Return on Equity (-5.29%), as it is currently unprofitable.